Clinical trial Recruiting at 15 sites Interventional Ages Any age to 8 Months

Hydrolyzed rice protein formula to support growth and tolerance in infants with cow's milk protein allergy

Official title: Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy: a Randomized Nutritional Clinical Study

Run by Société des Produits Nestlé (SPN) · NCT06633250 · Data updated 2026-11-12

This trial will test whether a hydrolyzed rice protein-based infant formula helps babies with cow's milk protein allergy grow as well and tolerate feeding as well as a control formula.

More Cow Milk Allergy trials

Quick facts

Study typeInterventional
AgesAny age to 8 Months
SexAll
Enrollment104 (estimated)
SponsorSociété des Produits Nestlé (SPN)
Industry-sponsored
Locations19 sites (Berlin and 18 other locations)
StatusRecruiting
StartedOctober 25, 2024
Main results expectedAugust 2026
Study endsAugust 2026
Registry record updatedDecember 26, 2025
Trial IDNCT06633250 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Term singleton infants aged ≤8 months who are fully formula-fed (no breast milk), have suspected or confirmed CMPA, are on a strict cow's milk elimination diet, and meet the listed birth weight and consent requirements.

Probably not a fit

Infants who are still breastfeeding, born preterm, have other serious medical conditions, or require amino-acid-based formulas for severe IgE-mediated allergy are unlikely to benefit from this formula.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Term infants up to 8 months with suspected or confirmed cow's milk protein allergy who are fully formula-fed will receive either a hydrolyzed rice protein-based test formula or a control formula while remaining on a strict cow's milk elimination diet. The main goal is to show that growth on the test formula is not worse than growth on the control formula; gastrointestinal tolerance, health-related quality of life, and formula acceptability will also be recorded. Measurements include growth parameters and parent-reported tolerance and quality-of-life questionnaires collected during follow-up visits at participating pediatric centers. The trial is conducted at tertiary hospitals in Germany and Italy and is sponsored by a commercial formula manufacturer.

Why it matters

Potential benefit: If successful, this formula could offer a well-tolerated, non-dairy option that supports normal growth in infants with cow's milk protein allergy.

How similar studies have gone: Previous smaller studies and clinical experience suggest hydrolyzed rice-based formulas can support growth and are tolerated by many infants with CMPA, but the evidence base is smaller than for extensively hydrolyzed cow's milk or amino-acid formulas.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Written informed consent has been obtained from at least one parent (or legally acceptable representative \[LAR\]), if applicable)
2. Infant gestational age ≥ 37 completed weeks
3. Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
4. Singleton birth
5. Infant age ≤ 8 months
6. Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk
7. Suspected CMPA as per standard clinical practice and in conjunction with at least 2 symptoms present from the list shown below:

   1. Inconsolable crying, regurgitation, liquid stools or constipation, skin atopic lesion, cow's milk provoked temporary urticaria/angioedema or vomiting, bloody streaks in stool, or respiratory symptoms
   2. For diagnosis based on either a positive IgE blood test, skin prick test or food challenge, only at least 1 symptom from above list needs to be present
8. Infant is receiving a strict cow's milk elimination diet and will continue receiving this diet until the completion of the study
9. Infant's parent(s)/LAR is of legal age of majority, must have parental authority, must understand the informed consent form and other study documents, and is willing and able to fulfill the requirements of the study protocol

Exclusion Criteria:

1. History of intolerance to eHF formula
2. Any chronic medical diseases (except atopic eczema), chromosomal or major congenital anomalies (based on medical history and/or commonly performed diagnostic criteria)
3. Major gastrointestinal disease / abnormalities (other than CMPA)
4. Known or suspected lactose intolerance or malabsorption
5. Known or suspected soy allergy
6. Glucose-galactose malabsorption
7. Rice protein allergy or intolerance (e.g., rice protein-induced enterocolitis syndrome).
8. Immunodeficiency
9. Persistent wheeze or chronic respiratory disease
10. Severe uncontrolled eczema
11. History of severe anaphylactic reaction (e.g., requiring ≥ 2 doses of epinephrine) to cow's milk or breast milk at any time prior to enrollment
12. Weight-for-age value \< -2 or \> 2 standard deviations from the WHO Child Growth Standards median at enrollment
13. Height-for-age \< -2 or \> 2 standard deviations from the WHO Child Growth Standards median at enrollment
14. Infant's parent has other medical or psychiatric condition that, in the judgement of the investigator, would make the infant inappropriate for entry into the study
15. Currently participating or having participated in another interventional clinical study within 4 weeks prior to enrollment

Where it's running

  • Charité Universitätsmedizin Berlin
    Berlin, Germany
    Recruiting
  • Azienda Ospedaliera Universitaria Federico II
    Naples, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Italy
    Recruiting
  • AO Ordine Mauriziano
    Turin, Italy
    Recruiting
  • Poliklinika Ginekologiczno-Położnicza Arciszewscy
    Bialystok, Poland
    Recruiting
  • Centrum Medyczne Pratia
    Bydgoszcz, Poland
    Recruiting
Show 13 more locations
  • IN-VIVO Bydgoszcz
    Bydgoszcz, Poland
    Recruiting
  • Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
    Bydgoszcz, Poland
    Recruiting
  • Vitamed Galaj i Cichomski
    Bydgoszcz, Poland
    Recruiting
  • BioMedical Centers
    Janki, Poland
    Recruiting
  • Jagiellonian University Medical College
    Krakow, Poland
    Recruiting
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika
    Lodz, Poland
    Recruiting
  • ETG Lublin
    Lublin, Poland
    Recruiting
  • Korczowski Bartosz Gabinet Lekarski
    Rzeszów, Poland
    Recruiting
  • Alergo-Med Specjalistyczna Przychodnia Lekarska
    Tarnów, Poland
    Recruiting
  • AOUP Ospedale Santa Chiara
    Pisa, Italy
    Completed
  • Ospedale Pediatrico Bambino Gesu
    Rome, Italy
    Not yet recruiting
  • Centrum Medyczne Plejady
    Krakow, Poland
    Completed
  • University Hospital of Warsaw
    Warsaw, Poland
    Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.